Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer's disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/07/16 | $47,000,000 | Series E |
Merieux Developpement Shire Strategic Investment Group | undisclosed |
